
Cassava Sciences Inc (NASDAQ:SAVA) shares are trading higher Tuesday morning after a Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of $2.25 each.
What To Know: Barry’s insider purchase injects a dose of confidence following the company’s decision earlier this year to discontinue the development of its Alzheimer’s drug, simufilam.